Podcasts about Atrial fibrillation

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Healthcare Expenditure on Atrial Fibrillation in the United States: The Medical Expenditure Panel Survey 2016 to 2021.

Dr. Emile Daoud, Deputy Editor of JACC Clinical Electrophysiology discusses Premature Ventricular Complexes after Ablation for Paroxysmal Atrial Fibrillation and Recurrent Atrial Arrhythmias: admIRE Subanalysis.

Assessing Recurrence Following Pulsed Field Ablation for Atrial Fibrillation   Guest: Nicholas Tan, M.D., M.S. Host: Anthony H. Kashou, M.D.   Pulsed field ablation has been rapidly adopted across the United States since FDA approval was granted 1 year ago, due to its excellent acute efficacy, favorable safety profile, and fast workflow. However, recurrences post-ablation are comparable to that of previously established modalities, making this a significant hurdle that has yet to be overcome. Changes to mapping/ablation strategies, updates to PFA parameters, autonomic modulation, and combination modality ablations (PFA/RFA) offer some avenues for improvement   Topics Discussed:  What is pulsed field ablation (PFA) and how does it differ from previously established modalities of ablation such as radiofrequency and cryoablation? What are the recurrence rates post-PFA and how do they compare with other modalities? In patients who undergo redo ablations following an index PFA procedure, what are the most common causes (i.e. reconnection of pulmonary veins versus new sites)? How do you think PFA will evolve in the coming years   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

BUFFALO, NY — May 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 10, 2025, titled “Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation.” In this study, first author Masahiko Takahashi and corresponding author Keisuke Okawa led a research team from Kagawa Prefectural Central Hospital and Hyogo Medical University that investigated whether Factor Xa inhibitors (Xa-Is)—a type of blood thinner—can reduce the risk of heart-related complications in patients over 80 with nonvalvular atrial fibrillation (NVAF). The study found that patients using Xa-Is experienced significantly fewer cardiovascular problems than those on other anticoagulants. This finding is especially relevant, as older adults face a high risk of both stroke and heart disease. Atrial fibrillation is a common heart rhythm disorder, particularly in the elderly, that increases the risk of blood clots, heart failure, and stroke. Anticoagulants are often prescribed to prevent clots, but not all types have the same effects on heart health. This study focused on comparing Xa-Is—specifically rivaroxaban, apixaban, and edoxaban—with commonly used drugs such as warfarin and dabigatran. Researchers followed more than 1,000 patients aged 80 and above for up to five years to assess the long-term impact of these medications on cardiovascular outcomes. Patients who used Xa-Is had significantly lower rates of heart failure, artery disease, and cardiovascular death. The risk of cardiovascular problems in the Xa-I group was less than half that of those on non-Xa-I medications. These benefits remained even after adjusting for factors like age, existing heart conditions, and kidney function. Additionally, stroke and all-cause death rates were notably lower in the Xa-I group. “Xa-Is may be useful for not only anticoagulation but also the prevention of cardiovascular events in very old patients with NVAF.” What makes Xa-Is different, according to the researchers, is their ability to inhibit a specific biological pathway—known as Factor Xa–PAR2—that contributes to inflammation, fibrosis, and damage in blood vessels and heart tissue. This effect extends beyond their traditional role in preventing blood clots. Although the study was conducted at a single medical center in Japan, its rigorous design and long follow-up period enhance the reliability of the findings for real-world clinical decision-making. While further studies, especially across multiple centers, are needed to confirm the full range of benefits, this study strongly suggests that Xa-Is may offer broader cardiovascular protection for very old patients. The findings could influence how clinicians choose blood thinners for elderly individuals with atrial fibrillation, potentially improving both survival and quality of life in this growing population. DOI - https://doi.org/10.18632/aging.206238 Corresponding author - Keisuke Okawa - k-ookawa@chp-kagawa.jp Video short - https://www.youtube.com/watch?v=YtbYpfVDVDI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206238 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Factor Xa inhibitor, atrial fibrillation, older patient, cardiovascular events To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

Join host Michael S. Lloyd, MD, FHRS and episode guests Ante Anic, MD and Konstantinos Vlachos, MD as they discuss the recent article Repeat Procedures after Pulsed Field Ablation for Atrial Fibrillation, the MANIFEST-REDO Study, from Europace. This episode was recorded in-person at EHRA 2025. Bonus video footage of the episode is available on heartrhythm265.org.   https://www.hrsonline.org/education/TheLead https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euaf012/7958418   Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Arga Medtech, Circa Scientific Membership on Advisory Committees: Boston Scientific Contributor Disclosure(s): A. Anic: Honoraria/Speaking/Consulting: Boston Scientific Research: Biosense Webster, Inc., AtaCor Medical Inc., Arga Medtech K. Vlachos: Nothing to disclose.

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

In atrial fibrillation (A-Fib) and atrial flutter (A-Flutter) the electrical impulse for cardiac contraction is in the atria but isn't the normal pacemaker of the heart, the SA node. The ECG characteristics of A-Fib and A-Flutter. Recognition and treatment of unstable patients in A-Fib/Flutter with rapid ventricular response (RVR).Suggested energy settings for synchronized cardioversion of unstable patients with a narrow complex tachycardia. Team safety when cardioverting an unstable patient in A-FIB/Flutter.Adenosine's role for stable SVT patients with underlying atrial rhythms.Treatment of stable patients in A-Fib/Flutter with RVR. For other medical podcasts that cover narrow complex tachycardias, visit the pod resource page at passacls.com. Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Interview with Leonoor F. J. M. Wijdeveld, BSc and Sean J. Jurgens, MD, MSc, PhD, authors of Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation. Hosted by Sharlene Day, MD. Related Content: Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation Genetic Testing in Early-Onset Atrial Fibrillation

Interview with Leonoor F. J. M. Wijdeveld, BSc and Sean J. Jurgens, MD, MSc, PhD, authors of Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation. Hosted by Sharlene Day, MD. Related Content: Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation Genetic Testing in Early-Onset Atrial Fibrillation

This special electrophysiology-themed issue of JACC, summarized by Dr. Valentin Fuster, dives into cutting-edge research on atrial fibrillation, pulsed field ablation, sudden cardiac arrest in athletes, and preventive strategies in congenital heart disease. From new therapies like finerenone to breakthrough mapping techniques, this episode captures the evolving sophistication and promise of arrhythmia management in modern cardiology.

This special electrophysiology-themed issue of JACC, summarized by Dr. Valentin Fuster, dives into cutting-edge research on atrial fibrillation, pulsed field ablation, sudden cardiac arrest in athletes, and preventive strategies in congenital heart disease. From new therapies like finerenone to breakthrough mapping techniques, this episode captures the evolving sophistication and promise of arrhythmia management in modern cardiology.

This week on Health and Longevity, Dr. John Westerdahl's featured guest is Steven Ryan, Ph.D. - Author of Beat Your A-Fib - The Essential Guide to Finding Your Cure. Dr. Ryan discusses Atrial Fibrillation, an emerging new epidemic in cardiovascular disease. A former A-Fib patient himself, Dr. Ryan is a noted healthcare educator and advocate for patients suffering from Atrial Fibrillation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS.

In this podcast, Dr. Valentin Fuster reviews the impact of catheter ablation on atrial fibrillation progression, summarizing a state-of-the-art article published in JACC. It explores how catheter ablation modifies the disease's mechanisms, reduces progression to persistent atrial fibrillation, and improves cardiovascular outcomes, suggesting that earlier intervention leads to better long-term results.

Mark Goddard, Vice President of Clinical Services at InfoBionic.Ai, a leading authority in cardiac remote monitoring. A registered nurse with over 20 years of experience in clinical electrophysiology, Mark has pioneered service lines across ambulatory ECG, cardiac event monitoring, mobile telemetry and heart failure management in hundreds of institutions. He's also a certified Clinical Cardiac Device Specialist with deep knowledge of subcutaneous monitoring and AI-assisted diagnosticsIn this episode, we explore how AI and real-time ECG data are revolutionising arrhythmia detection, heart failure prediction and patient engagement especially for high-risk groups like those with A-Fib. Mark shares practical insights from the front lines of cardiac care, how to tell genuine innovation from AI hype and why the future of diagnostics may lie beyond traditional heart monitoring. We also cover clinical implementation challenges, device design for older populations and the fine line between wellness tracking and medical-grade careTimestamps:[00:00:27] AI-Powered ECG: From Novelty to Necessity[00:03:28] How Clinicians Are Separating Hype from Reality[00:05:07] Why Near Real-Time Beats Traditional ECG Monitoring[00:08:49] A-Fib and the Global Data Gap[00:11:36] When Good Tech Goes Bad: Early Pacemaker Mistakes[00:13:30] Hospitals, Homes and the Future of Cardiac Care[00:19:59] AI vs Machine Learning: What's the Real Difference?Get in touch with Mark - https://www.linkedin.com/in/mark-goddard-035ab427/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Dr. Ziv Harel discusses findings from his study, "Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial," with JASN Deputy Editor Manjula Kurella Tamura.

With Giovanni Donato Aquaro, University of Pisa - Italy, and Carmelo De Gori, Fondazione Monasterio, Pisa - Italy. Link to editorial Link to paper  

In this episode of Docs in a Pod, host Gina Galaviz sits down with Dr. Rajay Seudath, from Optum - University  to break down atrial fibrillation (AFib)—a common but serious heart rhythm disorder. They'll discuss what causes AFib, its symptoms, potential complications, and the latest treatment options. Whether you're a patient, caregiver, or just curious about heart health, this episode offers expert insights to help you better understand and manage this condition.  Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT:  Houston (1070 AM/103.3 FM The Answer)  7:00 to 7:30 pm CT:  Austin (KLBJ 590 AM/99.7 FM)  Docs in a Pod also airs on Sundays in the following cities:  1:00-1:30 pm ET:  Tampa (860 AM/93.7FM)   

Host Melissa E. Middeldorp, MPH, PhD, of the University Medical Centre Groningen & University of Adelaide, is joined by Andrea Robinson, MSN, ACNP, from Riverside Methodist Hospital, OhioHealth, and Jeroen ML Hendriks, PhD, RN, of Maastricht University Medical Centre, in this episode. The AF-EduCare trial investigated whether targeted patient education (delivered in-person or online) could reduce unplanned cardiovascular events in patients with atrial fibrillation (AF). The study found that while education improved patient knowledge, medication adherence, and risk factor awareness, it did not significantly reduce cardiovascular hospitalizations, emergency visits, or mortality compared to standard care. However, subgroup analyses suggested that younger patients, those without heart failure, and asymptomatic AF patients might benefit more from in-person education. The findings highlight that while education enhances patient engagement, comprehensive medical management and timely clinical interventions remain the key drivers of improved cardiovascular outcomes in AF care.  Join us for this in-depth conversation about the trial.   https://www.hrsonline.org/education/TheLead https://academic.oup.com/europace/article/27/1/euae211/7964628 Host Disclosure(s): M. Middeldorp: Nothing to disclose. Contributor Disclosure(s): A. Robinson: Honoraria/Speaking/Consulting: Medtronic, Inc., AtriCure, Inc., Biosense Webster, Inc. J. Kendriks: Honoraria/Speaking/Consulting: Biotronik   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode98

The wide array of cardiovascular implantable electronic devices (CIEDs) s may lead to confusion as to which one to use in what circumstances. Differentiating defibrillators, pacemakers, and loop recorders--as well as accessing and utilizing the collected data--is covered by guest Erin Nordstrom, BSN, RN, PHN, CV-B. Related PCNA courses:Choosing the Right Cardiac Pacing Device: https://pcna.net/online-course/choosing-the-right-cardiac-pacing-device-heart-failure-interventions/ 12-Lead ECG in the Clinical Setting: https://pcna.net/online-course/interpreting-and-applying-the-12-lead-ecg-in-clinical-settings/Managment of Atrial Fibrillation: https://pcna.net/online-course/management-of-atrial-fibrillation-from-a-to-z/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Interview with Steven J. Warach, MD, PhD, author of Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

Interview with Steven J. Warach, MD, PhD, author of Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

Justin Coleman speaks with Kate Ziser, a pharmacist at the Princess Alexandra Hospital in Brisbane, about her paper on the role of triple antithrombotic therapy in patients with atrial fibrillation following coronary stent insertion. Kate explains when triple therapy is indicated, the duration of therapy, and the step-down approach to antithrombotic therapy. Read the full article by Kate and her co-authors in Australian Prescriber.

In this standout episode of Next Steps 4 Seniors: Conversations on Aging, we’re bringing back an audience favorite: our eye-opening interview with Nurse Practitioner Liz Jackson from Henry Ford Hospital. Liz breaks down the B.E.F.A.S.T. method for spotting stroke symptoms early, dives into the different types of strokes, and explains why timing is everything when it comes to treatment. We also tackle the red flags of heart attacks, the sneaky signs of vascular disease (yes, even leg cramping!), and how managing conditions like high blood pressure and diabetes can be game-changers. Early detection = lives saved. This episode is packed with info that could protect you or someone you love. Listen now on your favorite podcast platform! Follow us on Facebook and Instagram @ConversationsOnAging Visit nextsteps4seniors.com and our foundation at nextsteps4seniorsfoundation.org Questions or ideas? Call 248-651-5010 or email hello@nextsteps4seniors.com Sponsorship inquiries: marketing@nextsteps4seniors.com Sponsored by Aeroflow Urology: You could qualify to receive incontinence supplies at no cost through insurance—discreetly delivered to your door. Visit aeroflowurology.com/ns4s to check eligibility. (*Some exclusions apply.)Learn more : https://nextsteps4seniors.com/See omnystudio.com/listener for privacy information.

For this episode we are joined by EBM guru, Dr. Brian Locke, who deftly breaks down all of our statistics questions. Is half dose DOAC as good as full dose DOAC for preventing VTE, and does it reduce bleeding risk? Can procalcitonin reduce duration of antibiotics for infections without compromising mortality rates? Can LLMs like GPT-4 help physicians manage patients better? Can reinforcement learning models predict when to start vasopressin in patients with septic shock? What is the risk of resuming anticoagulation in patients with atrial fibrillation and prior intracerebral hemorrhage? Is high flow nasal cannula as good as non-invasive ventilation for different types of respiratory failure? We answer all these questions and more!Half Dose DOAC for Long Term VTE Prevention (RENOVE)Biomarker-Guided Antibiotic Duration (ADAPT-Sepsis)GPT-4 Assistance for Physician PerformanceOptimal Vasopressin Initiation for Septic Shock (OVISS)DOACs for A fib after ICH (PRESTIGE-AF)High Flow Nasal Cannula vs NIV for Respiratory Failure (RENOVATE)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R

This interview features JACC Associate Editor Neha Pagidipati, MD, FACC, speaking with Maria Pabon, MD and Muthu Vaduganathan, MD about their study on finerenone's role in reducing new-onset atrial fibrillation in patients with cardio-kidney metabolic disease. The discussion covers the methodology and findings of a pooled analysis from three major clinical trials, highlighting finerenone's 17% risk reduction in atrial fibrillation, its potential mechanisms, and the need for greater diversity in clinical trial populations. They also touch on comparative evidence with other mineralocorticoid receptor antagonists and the broader implications for heart failure management.

Antithrombotic Therapy in AF

YES！我的高股息國際巨星來啦！ 國際級的高股息！？哪一檔這麼給力？ 00963 中信全球高股息，嚴選海外優息企業，掌握全球收益機會，3月首次除息囉！ 上除息行列！打開券商APP，輸入00963，3/17前買進即可參與，趕緊下單去！ https://user285523.pse.is/79hhbf -- 高雄美術特區3-4房全新落成，《惟美術》輕軌C22站散步即到家，近鄰青海商圈，卡位明星學區，徜徉萬坪綠海。 住近美術館，擁抱優雅日常，盡現驕傲風範！美術東四路29號 07-553-3838 https://user285523.pse.is/79p2pd －－－－以上訊息由 SoundOn 動態廣告贊助商提供－－－－ 飛碟聯播網《飛碟早餐 唐湘龍時間》2025.03.25 週二醫療保健單元 專訪：藥理學教授｜潘懷宗 主題：新抗凝血藥-阿貝西單抗的亮眼功效 心房顫動（Atrial Fibrillation）是心律不整最常見的原因，每個人終其一生會罹患心房顫動的機率高達25％。如果不就醫治療，好好保養，最嚴重的併發症為阻塞型腦中風和心臟衰竭，甚至失去生命，不可大意。 抗凝血劑一方面降低血栓形成，預防中風和週邊血管栓塞，但也會有出血併發症增加的擔憂，如果能有一款藥，既能降低血栓形成，又能減少出血併發症，那就是再好不過了。美國哈佛大學布萊根婦女醫院的研究人員針對新一型的抗凝血劑Abelacimab （阿貝西單抗）進行研究，並與現行的標準藥物Xarelto（拜瑞妥）互相比較，ClinicalTrials.gov編號為 NCT04755283。結果發現其出血併發症大幅度減少，相當令人滿意並超出預期，遂根據數據監測委員會的建議，提前完成了此次的臨床試驗，成果也已經發表在2025年1月的《新英格蘭醫學期刊》上。 「阿貝西單抗」不僅在心房顫動患者身上表現突出，也在膝關節置換中，優異亮眼，與現行預防靜脈血栓的克立生注射劑（Enoxaparin）相比，注射單劑量150毫克「阿貝西單抗」可使靜脈血栓發生率再降低80％，且不會增加出血風險。目前研究小組正在進一步實施的3期臨床試驗中，針對高風險、不適合使用現行抗凝血劑的心房顫動患者，給予150毫克劑量的「阿貝西單抗」或安慰劑，進行中風發生率和出血性事件的比較，希望能對這些原本無法用藥的病患，也能有所幫助，讓我們共同期望此藥正式上市的好消息。 潘懷宗教授 完整文章 https://www.chinatimes.com/opinion/20… #abelacimab #心房顫動#抗凝血#凝血劑#心臟#衰竭#中風#血栓#血管 ▶ 《飛碟早餐》FB粉絲團  / ufobreakfast  ▶ 飛碟聯播網FB粉絲團  / ufonetwork921  ▶ 網路線上收聽 http://www.uforadio.com.tw ▶ 飛碟APP，讓你收聽零距離 IOS：https://reurl.cc/3jYQMV Android：https://reurl.cc/5GpNbR ▶ 飛碟Podcast SoundOn : https://bit.ly/30Ia8Ti Apple Podcasts : https://apple.co/3jFpP6x Spotify : https://spoti.fi/2CPzneD KKBOX：https://reurl.cc/MZR0K4 -- Hosting provided by SoundOn

Dr. Ratika Parkash, MD, MSc, Deputy Editor of JACC Clinical Electrophysiology, discusses the reduction of atrial fibrillation burden after cryoballoon ablation in patients with early persistent atrial fibrillation

Atrial Fibrillation: Clinical ReviewThis full-length clinical review episode on atrial fibrillations is designed to help take your fund of knowledge to the next level!Visit https://www.pointofcaremedicine.com/review-article/atrial-fibrillation to see the online Clinical Review Article.Our mission is to create accessible and easy-to-use digital resources that help healthcare professionals tackle common clinical presentations at the point of care, without getting bogged down by unnecessary details or trivia.Timestamps00:00 Introduction to Atrial Fibrillation00:12 Key Takeaways01:13 Definitions02:17 Etiologies04:22 Pathophysiology07:28: Physical Exam08:18 Diagnostic Workup10:25 Treatment - Stroke Prevention14:17 Treatment - Rate Control16:13 Treatment - Rhythm Control19:05 Treatment - Risk Modification20:10 Clinical Pearls29:54 Review of Clinical Trials34:11 Additional Resources and ConclusionShow NotesReview ArticlesAtrial Fibrillation A Review Direct Oral Anticoagulants in Patients with ESRD Catheter ablation for atrial fibrillation: indications and future perspective Related ContentAfib with RVR Admission Template20 Atrial Fibrillation Facts Every Physician Needs to Know in 202510 Key Facts About Ablation for Atrial FibrillationCKD and Atrial Fibrillation: Navigating the Anticoagulation MazeDisclaimer: The content of this video and any associated media is meant for educational and information purposes only. RMO Medical Education does not provide medical advice, diagnosis, or treatment.

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2023:Hydrocortisone in Severe Community-Acquired Pneumonia (0:00 – 5:39).Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes (5:40 – 8:48).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (8:49 – 12:29).Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (12:30 – 17:49).Early versus Later Anticoagulation for Stroke with Atrial Fibrillation (17:50 – 23:38).And for the Good Stuff:The Beckham docuseries on Netflix (23:39 – 24:15)Upside Drinks (24:16 – 26:04).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Melissa E. Middeldorp, MPH, PhD, University Medical Centre, Groningen & University of Adelaide, is joined by So-Ryoung Lee, MD, PhD, Seoul National University Hospital, and Adrian D. Elliott, PhD, University of Adelaide/Royal, Adelaide Hospital, to discuss a study that compares atrial fibrillation (AF) epidemiology and risk factors between the UK Biobank (a predominantly European cohort) and the Korean NHIS-HEALS cohort to explore racial differences in AF incidence. Findings revealed that AF was more prevalent in the UK cohort than in the Korean cohort, with BMI and smoking showing stronger associations with AF risk in the UK population. Despite these differences, several risk factors, including hypertension and diabetes, were common predictors in both populations. The study highlights the complex interplay of lifestyle and healthcare system factors along with analysis of different large cohort studies in AF development and underscores the need for population-specific risk assessment and prevention strategies. https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)00128-6/fulltext Host Disclosure(s): M. Middeldorp: Nothing to disclose.   Contributor Disclosure(s): S. Lee: Nothing to disclose. A. Elliott: Nothing to disclose.   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode96

Edward Gerstenfeld, MD, Executive Editor of JACC: Clinical Electrophysiology discusses a recently published original research paper on pulsed-field vs thermal catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

Can you exercise with AFib? Know someone with AFib—maybe a parent or loved one—who wants to stay active but isn't sure how? In this episode, Dr. Sean Swearingen, sports cardiologist, breaks down exactly how you can stay active while managing atrial fibrillation, without putting your heart at risk. Whether you're new to AFib or just looking to get back into exercise, you'll get expert advice on safe workouts, heart health monitoring, and when to reach out to your cardiologist. In This Episode, You'll Learn: Exercising with AFib: Why staying active is crucial for your heart, and how to safely incorporate exercise into your routine if you have AFib. How to Start Safely: Starting or returning to exercise after an AFib diagnosis? Dr. Swearingen shares the best tips for building up your fitness gradually and safely. Heart Rate Monitoring: The best tools to track your heart health during workouts, including the Zio Patch and Apple Watch, to make sure your AFib stays under control. When to Consult Your Cardiologist: How to know when it's time to check in with your cardiologist, and how to get personalized advice on exercising with AFib. The Role of Sports Cardiology: Why seeing a sports cardiologist can be a game-changer for safely managing AFib while staying fit. Who Should Listen: Anyone living with, or knows someone living with, AFib who wants to get back into exercise safely. People interested in sports cardiology and how it can help you stay active with heart conditions. Anyone who wants to learn to have a healthier heart Resources Mentioned in This Episode: Rush University Sports Cardiology: Learn more about Dr. Swearingen's sports cardiology practice here. Apple Watch: A great tool for tracking heart rate and rhythm during exercise. Find out more here. Zio Patch: Continuous heart monitoring for those with AFib. Learn more here. American Heart Association: Exercise tips and guidelines for those with heart conditions. Check out their recommendations here. Why You Should Listen: If you've been diagnosed with AFib, you're not alone. But that doesn't mean you have to stop being active. Dr. Swearingen gives you the expert advice you need to stay safe, stay fit, and stay healthy with AFib. Don't miss out—tune in now! Connect with Us: Please sign up for our SUBSTACK so you can forward this information to all your friends inboxes! For more episodes, merch, or to send us direct messages: Website: https://yourdoctorfriendspodcast.com Email: yourdoctorfriendspodcast@gmail.com Socials: Follow @your_doctor_friends on Instagram, TikTok, and YouTube. DM or send us a voice memo—we might feature it on the show! atrial fibrillation, AFib, exercise with AFib, heart health, sports cardiology, heart monitoring devices, Zio Patch, Apple Watch, managing AFib with exercise, post-COVID heart health, exercise guidelines for heart disease, living with AFib, sports cardiology, arrhythmias, fitness for heart patients

Deep Chandh Raja, MBBS, MD, PhD, Australian National University, Kauvery Hospital, is joined by Dhiraj Gupta, MBBS, MD, Liverpool Heart and Chest Hospital, and Dominik K Linz, MD, PhD, Maastricht University Medical Center, to discuss a international position paper, developed by the Working Group of the Signal Summit, highlights the challenges in understanding and treating atrial fibrillation (AF), the most common arrhythmia in adults. Despite technological advancements in pulmonary vein isolation (PVI), progress in understanding AF mechanisms, structural changes, and phenotypic differences has been limited due to inconsistent terminology, suboptimal mapping techniques, and the complex nature of AF itself. The paper aims to establish clearer definitions, promote standardized approaches, and propose research pathways to improve AF therapies and patient outcomes.  https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(24)03564-1/fulltext Host Disclosure(s): D. Raja: Nothing to disclose.   Contributor Disclosure(s): D. LInz: Nothing to disclose. D. Gupta: Research: Medtronic Bakken Research Center, Biosense Webster, Inc., Boston Scientific   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode94

Send us a textMost pills are taken daily, and many vaccines protect for around a year, but could medical device products last even longer? In this episode of the Monday Morning Minute, Dr. Michael Koren joins Kevin Geddings and explains what medical devices are and how they can make long-term differences for patients. The two discuss device treatments for diabetes, weight loss, atrial fibrillation, blood pressure, and how AI may be able to help.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on AppleWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Our guest today is Evelyn Gamble.  Evelyn is a dedicated healthcare worker and passionate heart disease advocate. With a deep commitment to improving health outcomes, Evelyn uses her personal and professional experiences to raise awareness about heart health, particularly for young adults. As a strong voice for change, she aims to inspire others to take proactive steps in managing their heart health and to advocate for better care and resources for those affected by heart disease.     Definition: A heart arrhythmia, also known as a cardiac arrhythmia, is an abnormal rhythm of the heart. It occurs when the electrical impulses that control the heart's contractions do not function properly.    Causes:    Heart arrhythmias can be caused by a wide range of factors, including:    Heart disease (e.g., coronary artery disease, heart failure) Electrolyte imbalances (e.g., low potassium or magnesium) Certain medications (e.g., stimulants, caffeine) Thyroid disorders Damage to the Vagus Nerve Stress Genetics    Types:    There are many different types of heart arrhythmias, which can be classified based on the rate and rhythm of the heart:    Tachycardia: A rapid heart rate (over 100 beats per minute)    Bradycardia: A slow heart rate (under 60 beats per minute)    Atrial fibrillation: A quivering or irregular rhythm of the upper chambers of the heart (atria)    Ventricular fibrillation: A life-threatening rhythm where the lower chambers of the heart (ventricles) contract irregularly and chaotically    Premature beats: Extra heartbeats that occur early in the rhythm    Symptoms:    Some people with heart arrhythmias may not experience any symptoms. Others may have symptoms such as:    Palpitations (feeling like the heart is racing or fluttering), Chest pain or discomfort, Dizziness or lightheadedness, Fainting, and Shortness of breath.    Diagnosis and Treatment:    To diagnose a heart arrhythmia, your doctor will likely perform a physical exam, ask about your medical history, and take an electrocardiogram (ECG). Treatment options depend on the type and severity of the arrhythmia and may include:    Medications (e.g., beta-blockers, antiarrhythmics) Lifestyle changes (e.g., exercise, stress management) Surgery (e.g., ablation procedure) Implantable devices (e.g., pacemakers, defibrillators)    Outlook: The outlook for people with heart arrhythmias varies depending on the underlying cause and severity of the condition.

We're back, after a brief hiatus! Today we talk about duration of therapy for bacteremia, Factor XI inhibition for atrial fibrillation, whether to stop ACEi or ARB before elective surgery, and whether GLP-1 agonists are beneficial in heart failure with preserved ejection fraction. Go to minute 7:30 to skip the banter. 7 vs 14 Days of Antibiotics for Bacteremia (BALANCE)Abelacimab vs Rivaroxaban for Atrial Fibrillation (AZALEA-TIMI-71)Asenduxian vs Apixaban for Atrial Fibrillation (OCEANIC-AF)ACEi or ARB Discontinuation Before Surgery (STOP or NOT)Tirzepatide for HFpEF and Obesity (SUMMIT)Music from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/dopeLicense code: NP8HLP5WKGKXFW2R

Join CardioNerds EP Council Chair Dr. Naima Maqsood and Episode Lead Dr. Jeanne De Lavallaz as they discuss the results of the ARREST-AF Trial with expert faculty Dr. Prashanthan Sanders and Dr. Mehak Dhande. The ARREST-AF trial enrolled 122 patients with a BMI of 27 kg/m2 or greater and at least one cardiovascular risk factor with either paroxysmal or persistent AF and were scheduled to undergo de novo AF ablation. They were randomized to an intensive risk factor management (RFM) program versus usual care. The RFM program addressed obesity, sleep apnea, HTN, HLD, tobacco, and alcohol abuse, whereas the usual care arm had a discussion of risk factors but without an extensive risk factor modification or follow-up program. The study population had a mean age of 60 years, a mean BMI of 33 kg/m2, and 56-60% of patients with persistent AF. A third of the study population was female. The trial showed a significant improvement in the primary endpoint of the percentage of patients free from atrial fibrillation after ablation in those receiving the intensive lifestyle RFM program. At the end of the 12.3-month follow-up period, 66% percent of patients in the RFM group were free from AF compared to 42% in the usual care group (HR 0.53, p = 0.03). The RFM group also showed significant improvement in AF symptom severity, decline in body weight, systolic blood pressure, glycemic control, and exercise capacity. On average, patients in the RFM arm lost 9 kg of weight compared to 1 kg in the control group. Similarly, systolic blood pressure decreased by 13.1 mmHg in the RFM group but increased by four mmHg in the control group. This episode was planned in collaboration with Heart Rhythm TV with mentorship from Dr. Daniel Alyesh and Dr. Mehak Dhande. CardioNerds Journal Club PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - The SUMMIT Trial Pathak, Rajeev K., et al. "Aggressive Risk Factor Reduction Study for Atrial Fibrillation and Implications for the Outcome of Ablation: The ARREST-AF Cohort Study." Journal of the American College of Cardiology, vol. 64, no. 21, 2014, pp. 2222–2231.